MX2007011908A - Metodo basado en el suministro local de sustancias activas para tratar enfermedades prostaticas. - Google Patents
Metodo basado en el suministro local de sustancias activas para tratar enfermedades prostaticas.Info
- Publication number
- MX2007011908A MX2007011908A MX2007011908A MX2007011908A MX2007011908A MX 2007011908 A MX2007011908 A MX 2007011908A MX 2007011908 A MX2007011908 A MX 2007011908A MX 2007011908 A MX2007011908 A MX 2007011908A MX 2007011908 A MX2007011908 A MX 2007011908A
- Authority
- MX
- Mexico
- Prior art keywords
- calcium
- barium
- magnesium
- active substances
- hydrated
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 208000017497 prostate disease Diseases 0.000 title 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 abstract 4
- 239000000919 ceramic Substances 0.000 abstract 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 abstract 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 abstract 2
- 239000001175 calcium sulphate Substances 0.000 abstract 2
- 235000011132 calcium sulphate Nutrition 0.000 abstract 2
- 230000000887 hydrating effect Effects 0.000 abstract 2
- 210000002307 prostate Anatomy 0.000 abstract 2
- OYLGJCQECKOTOL-UHFFFAOYSA-L barium fluoride Chemical compound [F-].[F-].[Ba+2] OYLGJCQECKOTOL-UHFFFAOYSA-L 0.000 abstract 1
- 229910001632 barium fluoride Inorganic materials 0.000 abstract 1
- 229910052916 barium silicate Inorganic materials 0.000 abstract 1
- HMOQPOVBDRFNIU-UHFFFAOYSA-N barium(2+);dioxido(oxo)silane Chemical compound [Ba+2].[O-][Si]([O-])=O HMOQPOVBDRFNIU-UHFFFAOYSA-N 0.000 abstract 1
- WAKZZMMCDILMEF-UHFFFAOYSA-H barium(2+);diphosphate Chemical compound [Ba+2].[Ba+2].[Ba+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O WAKZZMMCDILMEF-UHFFFAOYSA-H 0.000 abstract 1
- AYJRCSIUFZENHW-DEQYMQKBSA-L barium(2+);oxomethanediolate Chemical compound [Ba+2].[O-][14C]([O-])=O AYJRCSIUFZENHW-DEQYMQKBSA-L 0.000 abstract 1
- 229910000019 calcium carbonate Inorganic materials 0.000 abstract 1
- 235000010216 calcium carbonate Nutrition 0.000 abstract 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 abstract 1
- 229910001634 calcium fluoride Inorganic materials 0.000 abstract 1
- 239000001506 calcium phosphate Substances 0.000 abstract 1
- 229910000389 calcium phosphate Inorganic materials 0.000 abstract 1
- 235000011010 calcium phosphates Nutrition 0.000 abstract 1
- 239000000378 calcium silicate Substances 0.000 abstract 1
- 229910052918 calcium silicate Inorganic materials 0.000 abstract 1
- 235000012241 calcium silicate Nutrition 0.000 abstract 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 abstract 1
- 239000001095 magnesium carbonate Substances 0.000 abstract 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 abstract 1
- 235000014380 magnesium carbonate Nutrition 0.000 abstract 1
- ORUIBWPALBXDOA-UHFFFAOYSA-L magnesium fluoride Chemical compound [F-].[F-].[Mg+2] ORUIBWPALBXDOA-UHFFFAOYSA-L 0.000 abstract 1
- 229910001635 magnesium fluoride Inorganic materials 0.000 abstract 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 abstract 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 abstract 1
- 239000004137 magnesium phosphate Substances 0.000 abstract 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 abstract 1
- 229960002261 magnesium phosphate Drugs 0.000 abstract 1
- 235000010994 magnesium phosphates Nutrition 0.000 abstract 1
- 239000000391 magnesium silicate Substances 0.000 abstract 1
- 229910052919 magnesium silicate Inorganic materials 0.000 abstract 1
- 235000019792 magnesium silicate Nutrition 0.000 abstract 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 abstract 1
- 235000019341 magnesium sulphate Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describe un metodo para tratar enfermedades relacionadas con la prostata en un sujeto, el metodo comprende: i) opcionalmente administrar al sujeto una dosis de refuerzo inicial de una o mas sustancias activas o precursores, y ii) administrar localmente en la prostata una composicion farmaceutica de liberacion controlada que comprende una o mas sustancias activas en un portador ceramico biodegradable. El material ceramico hidratante biodegradable se puede seleccionar del grupo que consiste de las formas no hidratada o hidratada de sulfato de calcio, fosfato de calcio, carbonato de calcio, fluoruro de calcio, silicato de calcio, sulfato de magnesio, fosfato de magnesio, carbonato de magnesio, fluoruro de magnesio, silicato de magnesio, sulfato de bario, fosfato de bario, carbonato de bario, fluoruro de bario, silicato de bario o mezclas de los mismos. En una modalidad especifica, el material ceramico hidratante biodegradable es sulfato de calcio no hidratado o hidratado.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200500452 | 2005-03-31 | ||
| PCT/EP2006/003194 WO2006103112A2 (en) | 2005-03-31 | 2006-03-31 | Method for treating prostate diseases based on local delivery of active substances |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007011908A true MX2007011908A (es) | 2008-02-07 |
Family
ID=35044589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007011908A MX2007011908A (es) | 2005-03-31 | 2006-03-31 | Metodo basado en el suministro local de sustancias activas para tratar enfermedades prostaticas. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8936809B2 (es) |
| EP (1) | EP1865924B1 (es) |
| JP (2) | JP5635231B2 (es) |
| KR (2) | KR20140014294A (es) |
| CN (1) | CN101160116B (es) |
| AU (1) | AU2006228675B2 (es) |
| CA (1) | CA2602776C (es) |
| DK (1) | DK1865924T3 (es) |
| ES (1) | ES2557988T3 (es) |
| HU (1) | HUE026158T2 (es) |
| IL (1) | IL185690A0 (es) |
| MX (1) | MX2007011908A (es) |
| NO (1) | NO338679B1 (es) |
| PL (1) | PL1865924T3 (es) |
| RU (1) | RU2404747C2 (es) |
| WO (1) | WO2006103112A2 (es) |
| ZA (1) | ZA200708066B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006103112A2 (en) * | 2005-03-31 | 2006-10-05 | Lidds Ab | Method for treating prostate diseases based on local delivery of active substances |
| CN102227228A (zh) * | 2008-11-27 | 2011-10-26 | 利德斯公司 | 羧甲基纤维素控制一种或多种生物吸收型陶瓷组合物的可推射性和固化时间的应用 |
| RU2606169C2 (ru) * | 2011-04-05 | 2017-01-10 | Эдж Терапьютикс | Система интравентрикулярной доставки лекарственного средства для улучшения исхода после повреждения головного мозга, нарушающего мозговое кровообращение |
| RU2519407C2 (ru) * | 2011-09-21 | 2014-06-10 | Виктор Павлович Горелов | Способ трансуретральной резекции предстательной железы, предшествующий брахитерапии рака простаты |
| GB201318862D0 (en) * | 2013-10-25 | 2013-12-11 | Glaxosmithkline Biolog Sa | Calcium fluoride compositions |
| GB201318858D0 (en) * | 2013-10-25 | 2013-12-11 | Glaxosmithkline Biolog Sa | Calcium fluoride compositions |
| US10912933B2 (en) | 2014-08-19 | 2021-02-09 | The Regents Of The University Of California | Implants for localized drug delivery and methods of use thereof |
| CA3026454C (en) | 2015-06-04 | 2023-07-04 | Crititech, Inc. | Collection device and methods for use |
| EP3854381A1 (en) | 2016-04-04 | 2021-07-28 | Crititech, Inc. | Methods for solid tumor treatment |
| CA3063420A1 (en) | 2017-06-09 | 2018-12-13 | Crititech, Inc. | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |
| WO2018231908A1 (en) | 2017-06-14 | 2018-12-20 | Crititech, Inc. | Methods for treating lung disorders |
| KR20250057947A (ko) | 2017-10-03 | 2025-04-29 | 크리티테크, 인크. | 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달 |
| WO2020061291A1 (en) * | 2018-09-20 | 2020-03-26 | Biovena Science, Llc | Flutamide microsphere-based arterial embolization for treating prostate disorders |
| US11911499B2 (en) | 2019-11-07 | 2024-02-27 | Resurge Therapeutics, Inc. | System and method for prostate treatment |
| US11338119B2 (en) * | 2020-03-20 | 2022-05-24 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| US11173291B2 (en) * | 2020-03-20 | 2021-11-16 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| CN115515657A (zh) * | 2020-03-20 | 2022-12-23 | 加利福尼亚大学董事会 | 用于局部药物递送的可植入药物递送设备 |
| US11344526B2 (en) * | 2020-03-20 | 2022-05-31 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| US11957654B2 (en) | 2022-01-29 | 2024-04-16 | Resurge Therapeutics, Inc. | Treating benign prostatic hyperplasia |
| US11602516B1 (en) | 2022-01-29 | 2023-03-14 | Resurge Therapeutics Inc. | Treating benign prostatic hyperplasia |
| JP2025505974A (ja) * | 2022-01-29 | 2025-03-05 | リサージ セラピューティクス，インコーポレイテッド | 良性前立腺過形成治療システム |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474813A (en) * | 1980-10-24 | 1984-10-02 | Schering Corporation | Pharmaceutical preparations comprising flutamide |
| US5614206A (en) * | 1995-03-07 | 1997-03-25 | Wright Medical Technology, Inc. | Controlled dissolution pellet containing calcium sulfate |
| US5795330A (en) * | 1996-10-10 | 1998-08-18 | Etex Corporation | Mixing device |
| ES2299183T3 (es) * | 1996-10-16 | 2008-05-16 | Etex Corporation | Composiciones bioceramicas. |
| US6391336B1 (en) | 1997-09-22 | 2002-05-21 | Royer Biomedical, Inc. | Inorganic-polymer complexes for the controlled release of compounds including medicinals |
| US5972384A (en) | 1997-10-01 | 1999-10-26 | University Of Maryland, Baltimore | Use of biologically active glass as a drug delivery system |
| WO2001010463A1 (en) * | 1999-08-05 | 2001-02-15 | Takeda Chemical Industries, Ltd. | Pastes with the sustained release of osteogenesis promoter |
| US6497901B1 (en) * | 2000-11-02 | 2002-12-24 | Royer Biomedical, Inc. | Resorbable matrices for delivery of bioactive compounds |
| US6645974B2 (en) * | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
| US20030147936A1 (en) * | 2002-02-07 | 2003-08-07 | Velayudhan Sahadevan | Prostatic hormonal implants treatment of prostate cancer |
| WO2004085418A2 (en) * | 2003-03-24 | 2004-10-07 | Luitpold Pharmaceuticals, Inc. | Xanthones, thioxanthones and acridinones as dna-pk inhibitors |
| GB0307082D0 (en) | 2003-03-27 | 2003-04-30 | Gyne Ideas Ltd | Drug delivery device and method |
| JP4927535B2 (ja) * | 2003-04-03 | 2012-05-09 | ジェシー エル エス オウ | 腫瘍を標的指向化する薬物を封入した粒子 |
| US20040224000A1 (en) | 2003-05-05 | 2004-11-11 | Romano Deghenghi | Implants for non-radioactive brachytherapy of hormonal-insensitive cancers |
| WO2005039537A1 (en) * | 2003-10-22 | 2005-05-06 | Lidds Ab | Composition comprising biodegradable hydrating ceramics for controlled drug delivery |
| WO2006103112A2 (en) * | 2005-03-31 | 2006-10-05 | Lidds Ab | Method for treating prostate diseases based on local delivery of active substances |
-
2006
- 2006-03-31 WO PCT/EP2006/003194 patent/WO2006103112A2/en not_active Ceased
- 2006-03-31 AU AU2006228675A patent/AU2006228675B2/en not_active Ceased
- 2006-03-31 ES ES06724133.1T patent/ES2557988T3/es not_active Expired - Lifetime
- 2006-03-31 KR KR1020137034233A patent/KR20140014294A/ko not_active Ceased
- 2006-03-31 EP EP06724133.1A patent/EP1865924B1/en not_active Expired - Lifetime
- 2006-03-31 JP JP2008503447A patent/JP5635231B2/ja not_active Expired - Fee Related
- 2006-03-31 PL PL06724133T patent/PL1865924T3/pl unknown
- 2006-03-31 US US11/910,162 patent/US8936809B2/en active Active
- 2006-03-31 KR KR1020077022037A patent/KR101380402B1/ko not_active Expired - Fee Related
- 2006-03-31 DK DK06724133.1T patent/DK1865924T3/en active
- 2006-03-31 RU RU2007140243/14A patent/RU2404747C2/ru active
- 2006-03-31 CA CA2602776A patent/CA2602776C/en not_active Expired - Lifetime
- 2006-03-31 HU HUE06724133A patent/HUE026158T2/en unknown
- 2006-03-31 MX MX2007011908A patent/MX2007011908A/es active IP Right Grant
- 2006-03-31 CN CN2006800100200A patent/CN101160116B/zh not_active Expired - Fee Related
-
2007
- 2007-09-03 IL IL185690A patent/IL185690A0/en active IP Right Grant
- 2007-09-19 ZA ZA2007/08066A patent/ZA200708066B/en unknown
- 2007-10-30 NO NO20075490A patent/NO338679B1/no unknown
-
2012
- 2012-11-27 JP JP2012258603A patent/JP2013067639A/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| IL185690A0 (en) | 2008-01-06 |
| PL1865924T3 (pl) | 2016-06-30 |
| EP1865924A2 (en) | 2007-12-19 |
| WO2006103112A3 (en) | 2006-12-21 |
| JP2013067639A (ja) | 2013-04-18 |
| US8936809B2 (en) | 2015-01-20 |
| RU2007140243A (ru) | 2009-05-10 |
| HUE026158T2 (en) | 2016-05-30 |
| AU2006228675B2 (en) | 2012-05-17 |
| ZA200708066B (en) | 2016-07-27 |
| JP5635231B2 (ja) | 2014-12-03 |
| US20080286205A1 (en) | 2008-11-20 |
| KR101380402B1 (ko) | 2014-04-02 |
| EP1865924B1 (en) | 2015-12-09 |
| CA2602776C (en) | 2013-10-22 |
| KR20080002776A (ko) | 2008-01-04 |
| CN101160116B (zh) | 2011-12-07 |
| DK1865924T3 (en) | 2016-02-29 |
| JP2008534546A (ja) | 2008-08-28 |
| RU2404747C2 (ru) | 2010-11-27 |
| CA2602776A1 (en) | 2006-10-05 |
| ES2557988T3 (es) | 2016-02-01 |
| CN101160116A (zh) | 2008-04-09 |
| NO20075490L (no) | 2008-01-02 |
| KR20140014294A (ko) | 2014-02-05 |
| WO2006103112A2 (en) | 2006-10-05 |
| AU2006228675A1 (en) | 2006-10-05 |
| NO338679B1 (no) | 2016-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007011908A (es) | Metodo basado en el suministro local de sustancias activas para tratar enfermedades prostaticas. | |
| EP2059205A4 (en) | METHOD FOR PRODUCING A SOLID FIRM FOR TREATMENT OF INJURED TISSUE | |
| MX344241B (es) | Sistema terapeutico transdermico para administrar la sustancia activa buprenorfina. | |
| IL194812A0 (en) | Integrated wound dressing system | |
| MX341883B (es) | Composicion farmaceutica para el tratamiento y prevencion de canceres. | |
| NZ602571A (en) | Micrornas that regulate muscle cell proliferation and differentiation | |
| WO2007133941A3 (en) | Therapeutic agent carrier | |
| NZ552047A (en) | Method of treatment of endobronchial infections | |
| CR10349A (es) | Tabletas de paracetamol de liberacion rapida | |
| WO2007127163A3 (en) | Cns-tumor treatment method and composition | |
| WO2005037323A3 (en) | Use of gro to treat or prevent inflammation | |
| SG178975A1 (en) | Indenone derivative and pharmaceutical composition comprising same | |
| WO2009067431A3 (en) | Controlled drug delivery using a zein layer modified with levulinic acid | |
| WO2005007072A3 (en) | Methods and pharmaceutical compositions for healing wounds | |
| NZ582556A (en) | Pharmaceutical composition for treating wounds and related methods | |
| IL151628A0 (en) | Combination therapies with vascular damaging activity | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| WO2005016265A3 (en) | Method for promoting bone growth | |
| WO2006050368A3 (en) | Therapeutic calcium phosphate particles iin use for aesthetic or cosmetic medicine, and methods of manufacture and use | |
| WO2011024168A3 (en) | Sustained release delivery systems for the prevention and treatment of head and neck cancers | |
| UA72927C2 (uk) | Композиція для лікування печінково-клітинного раку, що містить доцетаксель | |
| PL1603584T3 (pl) | Aplidyna do leczenia szpiczaka mnogiego | |
| DE50100833D1 (de) | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
| WO2007149543A3 (en) | Scar treatment using protein phosphatase inhibitors | |
| AR039162A1 (es) | Formulaciones de venlafaxina de liberacion extendida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |